EV Loftus et al. AP&T 2020; 52: 1343-1365. Full text: Long‐term safety of vedolizumab for inflammatory bowel disease
GEMINI long‐term safety (LTS) study results –initiated 2009:
- Enrolled patients (UC, n = 894; CD, n = 1349) received vedolizumab 300 mg IV every 4 weeks. Total of 7999 patient years of vedolizumab exposure.
- Vedolizumab discontinuation due to AEs occurred in 15% (UC) and 17% (CD) of patients.
- There were no new trends for infections, malignancies, infusion‐related reactions, or hepatic events, and no cases of progressive multifocal leukoencephalopathy
- Conclusion from authors: “The safety profile of vedolizumab remains favourable with no unexpected or new safety concerns.”
Related blog posts:
- Real-World Experience with Vedolizumab -Better Than Expected
- IBD Highlights from Recent Meetings with Commentary by Dr. Sandborn Explains Why Vedolizumab Should Be Considered a First Line Agent (2019)
- VICTORY Consortium Data for Vedolizumab 2018
- Vedolizumab More Effective Than Adalimumab for Ulcerative Colitis (Part 2)
- Vedolizumab More Effective Than Adalimumab for Ulcerative Colitis
- Vedolizumab vs Adalimumab for Infliximab Failure in Ulcerative Colitis –Which is Better?
- Getting the Most Out of Vedolizumab
AS Faye et al. Inflamm Bowel Dis 2020; 26: 1368-1376. Fertility Impact of Initial Operation Type for Female Ulcerative Colitis Patients (link includes video abstract)
Surgical options include Ileal pouch–anal anastomosis (IPAA), rectal-sparing colectomy with end ileostomy (RCEI), and ileorectal anastomosis (IRA). Conclusions based on “a patient-level state transition microsimulation in TreeAge Pro:”… “Despite an increased risk of infertility, our model results suggest that IPAA may be the optimal surgical strategy for female UC patients aged 20–30 years who desire children. For patients aged 35 years, RCEI should additionally be considered, as QALYs for RCEI and IPAA were similar.” In older age group, RCEI’s increase rate of childbirth (28%), decrease time to childbirth (14 months) and 77% reduction in IVF are important factors.
Related blog posts:
- IPAA (Pouch) for Crohn’s Disease and Indeterminate Colitis
- Toronto Consensus for Perianal Fistulizing Crohn’s Disease | gutsandgrowth
- What is Going On With Pouchitis? & No More Handshakes | gutsandgrowth
R Tariq et al. Inflamm Bowel Dis 2020; 26: 1415-1422. Efficacy of Fecal Microbiota Transplantation for Recurrent C. Difficile Infection in Inflammatory Bowel Disease
In this retrospective study with 145 patients, the overall cure rate of CDI after FMT was 80.0%, without CDI recurrence at median follow-up of 9.3 (range, 0.1–51) months. The authors concluded that “fecal microbiota transplantation effectively treats recurrent CDI in IBD patients but has no apparent beneficial effect on the IBD course.”
Related blog posts:
- Experimental Use of FMT for Ulcerative Colitis
- Fecal Microbial Transplantation -Evidence for Use Beyond Recurrent Clostridium Difficile | gutsandgrowth
- Ulcerative Colitis with Questionable Response to Fecal Transplant | gutsandgrowth
- Not So Promising: FMT for Ulcerative Coliits
- Early Results of FMT for IBD -Any Efficacy? | gutsandgrowth
Isle of Palms (July 2020)
gutsandgrowth 